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Peroxisome proliferator activated receptor g (PPARg) is a nuclear receptor and target for antidia-
betics that increase insulin sensitivity. Owing to the side effects of PPARg full agonists, research
has recently focused on non-activating ligands of PPARg, which increase insulin sensitivity with
decreased side effects. Here, we present the crystal structures of inverse agonist SR10171 and a
chemically related antagonist SR11023 bound to the PPARg ligand-binding domain, revealing an allo-
steric switch in the activation helix, helix 12 (H12), forming an antagonist conformation in the recep-
tor. H12 interacts with the antagonists to become fixed in an alternative location. Native mass
spectrometry indicates that this prevents contacts with coactivator peptides and allows binding of
corepressor peptides. Antagonists of related nuclear receptors act to sterically prevent the active
configuration of H12, whereas these antagonists of PPARg alternatively trap H12 in an inactive config-
uration, which we have termed the tumble and trap mechanism.
INTRODUCTION
Peroxisome proliferator activated receptor g (PPARg) is a ligand-activated nuclear receptor that plays
key roles in human metabolism and glucose homeostasis (Bruning et al., 2007; Kroker and Bruning,
2015; Taygerly et al., 2013; van Marrewijk et al., 2016). The receptor performs its function through obligate
heterodimerization with retinoid X receptor a (RXRa) to form a transcription factor capable of binding to
peroxisome proliferator response elements (PPRE) on DNA to initiate transcription of target genes (Chan-
dra et al., 2008). There are over 100 target genes of PPARg, which include genes involved in fatty acid meta-
bolism, glucose homeostasis, and adipogenesis. Endogenous ligands of PPARg include fatty acids, eicos-
anoids, and lipid metabolites.
PPARg has been the target of pharmaceuticals that have generated billions of dollars (USD) as antidia-
betics. The activity of PPARg is central to glucose homeostasis through modulating the response to insulin,
and a dysregulation in PPARg signaling contributes to the onset and perpetuation of type 2 diabetes. A
major class of antidiabetic treatments targeting PPARg is the thiazolidinedione (TZD) class of compounds,
which are synthetic full agonists of the receptor. These compounds have previously been effective in treat-
ing symptoms of type 2 diabetes, but their use has been restricted because of significant side effects, re-
sulting in their limited clinical use. These side effects are caused by supraphysiological activation of PPARg-
controlled genes, which dysregulate normal metabolic processes and include congestive heart failure,
weight gain, loss of bone mineral density, and renal fluid retention leading to edema (Bruning et al.,
2007; Choi et al., 2011; Wakabayashi et al., 2011). Phosphorylation of PPARg at Ser273 by Cdk5-regulated
ERK has been shown to correlate with obesity and insulin resistance, and PPARg ligands that improve in-
sulin sensitivity block this phosphorylation, resulting in PPARg target genes returning to a homeostatic
state (Banks et al., 2015; Choi et al., 2010, 2011). Antagonists of PPARg have been established as promising
alternatives to full agonists as clinically applicable antidiabetic agents (Choi et al., 2011, 2016; Marciano
et al., 2015a, 2015b; Stechschulte et al., 2016). These compounds that bind PPARg restore insulin sensitivity
without causing side effects associated with the activation of the receptor (Choi et al., 2011).
PPARg is composed of an intrinsically disorderedN-terminal AF1 domain (activation function 1 domain) that
binds co-regulators; a zinc-finger domain for DNA binding (DBD); a ligand-binding domain (LBD), which in-
cludes the AF2 (activation function 2) that binds ligands and co-regulators; and a mobile hinge region thatiScience 5, 69–79, July 27, 2018 ª 2018 The Author(s).
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joins the LBD andDBD. The crystal structure of the PPARg LBD in the presence of agonist ligands shows that
the domain conforms to the canonical nuclear receptor LBD architecture, consisting of 13 a-helices (1–12
and20) and a small b-sheet (Nolte et al., 1998). TheAF2 coactivator-binding surface, which is critical for deter-
mining the transcriptional output of PPARg through differential recruitment of co-regulators, comprises he-
lices H3–H5 and H12, with H12 oriented toward the space between H11, H4, and the H8-H9 interconnecting
loop. PPARg agonists stabilizeH12 as part of theAF2 surface through a network of hydrogenbondswithH12
to stabilize the helix in a position ideal for interacting with the AF2 as well as coactivators (Nolte et al., 1998).
Surprisingly, all crystal structures of the PPARg LBD to date, including the apo-LBD, have shown H12 in this
same ‘‘active’’ conformation. This puzzle was resolved by studies of the dynamics of the LBD, which indicate
that the LBD, and particularly H12, is highly mobile in the apo structure. Although no atomic-level structure
has been produced using nuclear magnetic resonance (NMR), the apo receptor produced few peaks in 3D
HNCO spectra, indicating that the LBD undergoes large levels of molecular motion when not bound to
ligand (Johnson et al., 2000). In contrast, when the full agonist rosiglitazone was added, the LBD was largely
stabilized, showing much less molecular motion overall. Further work using hydrogen-deuterium exchange
(HDX) confirmed these results, showing that full agonists, including rosiglitazone, strongly and selectively
stabilize H12 and H3, in contrast to partial agonists and antagonists (Bruning et al., 2007; Choi et al.,
2010; Hamuro et al., 2006). From this, it was hypothesized that the mechanism of action of full agonists is
to strongly stabilize theAF2 surface throughH12, allowing less of an entropic penalty for coactivator binding
leading to full transcriptional output. Thismechanismof stabilizing an active configuration of amobileH12 is
like that observed in related nuclear receptors, such as estrogen receptor a (ERa), estrogen receptor b (ERb),
and PPARa. It then seemed to follow that antagonists would destabilize the H12 interaction, as seen with
ERa, ERb, and PPARa, allowing corepressors to bind the corepressor-binding cleft, blocking agonism by
not allowing coactivators to bind. Our group recently showed that in the apo form, H12 exchanges between
many conformations (Chrisman et al., 2018). Several agonists and inverse agonists conformationally
constrain H12 into states that favor coregulator binding (Chrisman et al., 2018). The dynamic nature of
H12 has been further investigated using chemical cross-linking mass spectrometry (MS), which revealed
that, when the LBD is in the apo state, H12 samples a dynamic ensemble of distinct conformers, including
an antagonist conformation, which is stabilized upon the addition of an antagonist (Zheng et al., 2018).
These studies demonstrated that, in solution, H12 in the antagonist bound form of PPARg is located near
the H2-H3 region of the LBD (Zheng et al., 2018). However, no such antagonist locked state of H12 has
been discovered in crystal structures of PPARg to date, leaving the exact atomic details of the antagonist
and inverse agonist bound forms of PPARg undetermined.
Given the promise of antagonists of PPARg in the treatment of type 2 diabetes and certain cancer types
(Khandekar et al., 2018), it is important to understand their mechanism of action. For related receptors,
such as ERa, ERb, and PPARa, bound antagonists sterically clash with H12 in the active configuration (Brzo-
zowski et al., 1997; Pike et al., 1999; Srinivasan et al., 2017; Xu et al., 2002). We have termed this the ‘‘push
and tumblemechanism’’ in which the antagonists bound to these LBDs sterically clash with H12 (the ‘‘push’’)
and destabilize it in solution (the ‘‘tumble’’). However, in the existing X-ray crystal structures of antagonists
bound to the LBD of PPARg, H12 is in the agonist-like active conformation. This is possibly due to coacti-
vator peptides present forcing the complex to the active state or studies using ligands that are known to
adopt multiple conformations within the binding pocket in solution. Thus, although the PPARg antagonists
appear differently from antagonists of related receptors, as they do not sterically block the active H12
conformation, the allosteric switches required for corepressor binding remain unclear.
To further investigate the mechanism of antagonism in PPARg, we obtained X-ray crystal structures of the
PPARg LBD bound to two separate chemical antagonists, SR10171 and SR11023 (Figure S1), in the absence
of other peptides. Both compounds are a result of modification of the indole scaffold of SR1664, which im-
proves its pharmacokinetic properties (Stechschulte et al., 2016; Zheng et al., 2018). SR10171 partially re-
presses basal transcriptional activity of PPARg, classifying it as a partial inverse agonist (Stechschulte
et al., 2016), whereas SR11023 displays no transcriptional activity, classifying it as an antagonist (Zheng
et al., 2018) in transcriptional reporter assays. Both display high-affinity binding to the receptor, with
SR10171 having an IC50 of 220 nM and SR11023 having an IC50 of 108 nM in a competition displacement
assay (PPARg Lantha Screen) (Zheng et al., 2018). Both compounds compete with the full agonist rosiglita-
zone and right-shift its EC50 (Zheng et al., 2018). In addition, both compounds display insulin-sensitizing
properties. SR10171 possessed similar insulin-sensitizing efficacy as TZDs and SR1664 in obese diabetic
mice (Stechschulte et al., 2016) and in addition modulated osteoblast, osteocyte, and osteoclast activities,70 iScience 5, 69–79, July 27, 2018
Figure 1. Crystal Structures of SR10171 and SR11023 Bound to PPARg LBD
PPARg LBD main chain is shown in blue, with ligands shown as green (SR10171) and yellow (SR11023) sticks.
(A) Superposition of both ligand-bound structures.
(B) Comparison of crystal structures (blue) with rosiglitazone (orange sticks)-bound PPARg LBD (dark green) demonstrates
the change in helix 12 conformation. Nuclear receptor coactivator SRC-1 is shown in purple (PDB: 2PRG).indicating an anabolic effect on bone. Interestingly, SR10171 was a partial agonist in GAL-4 transactivation
reporter assays of PPARa with an EC50 of 1 mM (Stechschulte et al., 2016). SR11023 showed pS273 blocking
capabilities, consistent with antidiabetic properties of PPARg ligands (Zheng et al., 2018).
X-ray co-crystal structures of PPARgwith these ligands reveal that H12 adopts a non-agonist-like conforma-
tion, stabilized by interactions with the antagonist or inverse agonist bound in the ligand pocket. Unlike
antagonists of the ERa, ERb, and PPARa receptors, these ligands do not appear to sterically clash with
an agonist H12 conformation but rather trap it in an alternative conformation: a hold awaymechanism (tum-
ble and trap), rather than a push away mechanism (push and tumble). Native MS supports the idea that the
alternative H12 conformation inhibits transcription by removing important contacts with coactivators, mak-
ing the AF2 interaction interface accessible to corepressors.
RESULTS
SR10171 and SR11023 Induce an Alternate H12 Conformation in PPARg LBD
Co-crystal structures were obtained for both SR10171 and SR11023 bound to the PPARg LBD (Figure 1A),
with data refinement statistics in Table 1. The structures were solved in space group P6522 in both cases;
this is the first instance of this crystal form of PPARg. The asymmetric unit contained one subunit of the
PPARg LBD (monomeric). Most of the LBD (H1–H11) conformed to the canonical PPARg LBD structure,
with negligible variation in the global LBD fold compared with previous structures (root-mean-square
deviation [RMSD] of 0.71 Å across 238 Ca atoms and 0.69 Å RMSD over 234 Ca atoms compared with ro-
siglitazone-bound PPARg LBD, PDB: 2PRG). Superimposition of the crystal structures with each other dem-
onstrates their high similarity, with an RMSD of 0.50 Å over 265 Ca atoms.
Remarkably, the structures indicate an alternative conformation of H12, resembling an antagonist nuclear
receptor structure conformation, where H12 (residues following Leu465) is on the outside face of H3 ex-
tending toward the H20-H3 connecting loop distal to the remainder of the LBD (Figure 1B). This orientation
is the first structural evidence of an antagonist H12 conformation in PPARg.
The active conformation of H12 has been shown to be key for stabilizing the AF2 region to enable coacti-
vator binding. When in the agonist conformation, H12 is stabilized as part of the AF2 coactivator-binding
surface by agonists of PPARg, which bind across H3, between H3 and H7, and extend toward the AF2iScience 5, 69–79, July 27, 2018 71
Parameter SR10171 SR11023
PDB accession code 6C5Q 6C5T
Space group P 65 2 2 P 65 2 2
Cell dimensions
a, b, c (Å) 65.19, 65.19, 368.45 63.64, 63.64, 365.35
a, b, g () 90, 90, 120 90, 90, 120
Resolution range (Å) 61.4–2.4 (2.5–2.4) 19.7–2.75 (2.9–2.75)
Rmerge (%)
a 8.9 (5.6) 8.4 (4.1)
Rpim (%) 6.7 (82) 8.0 (83)
Mean (I)/s(I) 40.6 (1.5) 31.0 (1.6)
Completeness 99.0 (98.1) 97.8 (95.4)
Multiplicity 53.4 (55.4) 18.8 (19.9)
Structure refinement
Resolution range (Å) 41.6–2.4 19.7–2.75
Unique reflections 19,215 (1,837) 12,275 (1,165)
Rwork
b 0.249 (0.38) 0.254 (0.41)
Rfree
c 0.277 (0.423) 0.286 (0.402)
Total number of
Non-hydrogen atoms 2,293 2,150
Protein atoms 2,179 2,039
Ligand atoms 80 38
Water molecules 34 73
RMSD
Bond length (Å) 0.002 0.001
Bond angle (deg) 0.45 0.38
B-factors (Å2)
Overall 75.57 97.27
Average protein atoms 76.13 98.04
Average ligand atoms 68.64 90.96
Average solvent 55.63 78.83
Table 1. Crystallographic Data Statistics
Values in parentheses correspond to the last shell.
aRmerge = S jI  < I > j/S I.
bRwork = S jFo  Fcj/S jFoj for all data excluding data used to calculate Rfree.
cRfree = S jFo  Fcj/S jFoj, for all data.surface (Bruning et al., 2007; Nolte et al., 1998). Crystal structures of PPARg LBD bound to full agonist ro-
siglitazone show that the thiazole head group of rosiglitazone forms a network of hydrogen bonds with
His323 of H4, His449 of H11, and Tyr473 of H12, residues that constitute the AF2 surface (Chandra et al.,
2008; Gampe et al., 2000; Gelin et al., 2015; Liberato et al., 2012; Nolte et al., 1998). These interactions
mediated by TZDs stabilize the AF2 surface, strengthened by a hydrogen bond between His323 of H4
and Tyr473 of H12 (Nolte et al., 1998). H12 is central to this stabilizing network, enabling binding of72 iScience 5, 69–79, July 27, 2018
Figure 2. Hydrophobic Interactions Stabilizing H12 in the Antagonist Conformation
The hydrophobic tails of SR10171 (green sticks) and SR11023 (yellow sticks) mediate hydrophobic interactions between
H3 and H12 of the PPARg LBD (blue ribbons) to stabilize H12 at H3, away from the AF2 coactivator-binding surface.
Contributing hydrophobic residues are labeled and shown as sticks.transcription-promoting coactivators to the AF2 surface. In the SR10171/SR11023 structures, the ligands
are bound in the binding pocket distal to the AF2 surface, lacking direct interactions with constituents
of the AF2 surface. This leaves H12 unrestrained by the stabilizing AF2 network, with the remainder of
the AF2 making no contacts with the ligand and forming a conformation nearly identical to the apo state
structure. Specifically, H12 in these structures is held in place by a hydrophobic network composed of four
constituents: (1) the hydrophobic tail of SR10171 or SR11023; (2) side chains from loop regions surrounding
H3 and H12, including residues Phe264 and Leu465; (3) H12 residue side chains, including Tyr473 and
Lys474; and (4) H3 residue side chains Phe287 and Gly284. H12 is also held in place by one hydrogen
bond in both structures: Tyr477 side chain to Glu291 side chain (2.6 Å) for the SR10171 co-structure and
Gln283 side chain to the backbone oxygen atom of Ser464 (3.2 Å) in the SR11023-bound structure. The hy-
drophobic interactions stabilizing H12 can be viewed in Figure 2.
SR10171 and SR11023 Exhibit Unique Ligand-Binding Modes
Both the SR10171- and SR11023-bound crystal structures showed that ligand interaction is mostly through
hydrophobic interactions within the ligand-binding pocket, contributed by Ile262, Phe287, Leu330, Leu333,
Ile341, Ser342, and Tyr473. Both ligands are positioned between H3 and the beta sheet and wrap around
the solvent-exposed face of H3. Difference Fourier electron density in the ligand-binding pocket of the
SR10171-bound crystal structure showed that a second SR10171 ligand was bound simultaneously (refined
to 88% occupancy) and does not overlap with the binding pose of the first SR10171 conformation. This
could be a result of excessive ligand concentration (10 mM) during co-crystallization. Experiments to define
the lower affinity binding constant for the second binding event were unsuccessful owing to the hydropho-
bic nature of the compounds and the inability to keep them in solution at such high concentrations. The
presence of the additional SR10171 ligand appears to have no effect on the global fold of the LBD including
H12 compared with SR11023-bound PPARg LBD.
In addition to hydrophobic interactions, some residue-specific interactions were made between the li-
gands and the receptor (Figure 3). The terminal carboxyl of the higher occupancy SR10171 ligand forms
a 2.6 Å salt bridge with Arg288, and the carbonyl forms a 3.0 Å hydrogen bond with the amide of the lower
occupancy ligand, which forms a 3.1 Å hydrogen bond with His266. SR11023 forms a p-p interaction with
Phe287 in addition to hydrophobic interactions. Composite omit electron density maps of the ligands
modeled to the data can be found in Figure S2.iScience 5, 69–79, July 27, 2018 73
Figure 3. SR10171 and SR11023 Exhibit Unique Ligand-Binding Modes
Crystal structures reveal ligand-binding modes of (A) SR10171 (green sticks) and (B) SR11023 (yellow sticks) bound to
PPARg LBD (blue ribbons). The side chains of the major contributing residues are shown as blue sticks.Antagonists of PPARg Do Not Prevent LBD-Dependent Heterodimerization of PPARg
with RXRa
PPARg performs its active function through obligate heterodimerization with RXRa, where the two nuclear
receptors dimerize through their ligand-binding domains as well as in a DNA-dependent manner at their
DBDs (Chandra et al., 2008; Issemann et al., 1993; Kojetin et al., 2015). Interestingly, our structures were
monomeric in the crystal lattice, in contrast to other PPARg structures, which aremonomeric only in thepres-
ence of coactivator peptide. The PPARg LBD ordinarily forms a homodimer upon crystallization in a manner
analogous to PPARg/RXRa LBD heterodimerization. Prompted by the uniquely monomeric crystal struc-
tures, we hypothesized that SR10171 and SR11023 could potentially be exhibiting their repressive charac-
teristics by disrupting the LBD-dependent heterodimerization between PPARg and RXRa, which is required
for transcription of target genes. Native MS is well established to report on the stoichiometry of protein as-
semblieswith excellent correlation to solutionphase properties (Liko et al., 2016).We therefore investigated
PPARg/RXRa LBDheterodimerization in thepresenceof antagonists using nativeMS,which showed that the
heterodimer remained intact upon addition of antagonist or inverse agonist (Figure 4). This was indicated by
the relative abundanceof the freemonomers remaining unchanged comparedwith the apo spectra, consid-
ering the population of the heterodimer in the presence of antagonists is in both apo and holo forms. The
spectra also reveal an abundant holo heterodimer species in all cases of ligand addition, suggesting that
PPARg can bind to the ligands while in complex with RXRa LBD. Native PAGE of PPARg and RXRa LBDs
with increasing concentrations of SR10171 or SR11023 yielded results consistent with native MS (Figure S3).
Bothmethods demonstrated a consistent abundance of complexes corresponding to the PPARg/RXRa LBD
heterodimer even at high ligand concentrations. This evidence suggests that SR10171 and SR11023 do not
disrupt heterodimerization between PPARg and RXRa LBDs, and that repression of PPARg activity by the
ligands must occur through an alternate mechanism. This discovery indicates the importance of higher or-
der regulation of the PPARg transcriptional complex beyond interaction with RXRa, particularly the recruit-
ment of coactivators and corepressors to the PPARg/RXRa transcriptional complex.
SR10171 and SR11023 Cause Preferential Recruitment of Corepressors to PPARg
The recruitment of coactivators and corepressors is central to the regulation of transcription factor activity
(DiRenzo et al., 1997). As such, the conformation of H12 induced by SR10171 and SR11023 in the co-crystal
structures suggested a distinct binding site on the surface of PPARg that would enable corepressor bind-
ing. Native MS was employed to investigate antagonist and inverse agonist binding to the PPARg/RXRa
LBD heterodimer in the presence of coregulator peptides (Figure 4).
We used a coactivator peptide (SRC) and two corepressor peptides (SMRT and NCOR), as well as ligands
SR10171, SR11023, and rosiglitazone, to determine the effects of these ligands on coregulator binding. It
can be observed that, for all cases of peptide addition to the heterodimer in the absence of ligand (the bot-
tom spectra of each panel), there was an abundance of peptide-bound heterodimer (light green), suggest-
ing that each of the peptides can bind with sufficient affinity to the heterodimer in the absence of ligands. In74 iScience 5, 69–79, July 27, 2018
Figure 4. Native Mass Spectrometry Shows the Effect of Ligand Binding on PPARg/RXRa LBD Heterodimerization as well as Coregulator Peptide
Recruitment
Native mass spectrometry was performed on the PPARg/RXRa LBD heterodimer in the presence of SR10171, SR11023, or rosiglitazone. In the absence of
coregulator peptides, the spectra showed significant abundance of antagonist-bound heterodimer, and minimal change in the amount of free monomer
upon addition of antagonist, suggesting no disruption of the heterodimer upon ligand addition. Corepressor peptides NCOR1-3 and SMRT-2 and
coactivator peptide SRC2-2 were added to PPARg/RXRa LBD heterodimer to elucidate the coregulator binding capabilities of the holo heterodimer.
Ligands and peptides were added to heterodimer as labeled in a 1:1:1 molar ratio. Unbound coregulator peptides are denoted (*).the case of SRC, when ligand was added the SRC coactivator peptide was still able to bind, as indicated by
the presence of the dark green species corresponding to the peptide-bound holo heterodimer. This was
less abundant in the case of SR10171, where the abundance of this species was lesser compared with the
other spectra in this panel, suggesting that SR10171 does not bind as strongly to the SRC-bound hetero-
dimer, consistent with its function as an inverse agonist.
Analysis of the SMRT/NCOR spectra shows that compared with the apo spectra, there was a minimal abun-
dance of corepressor and rosiglitazone-bound species, as indicated by a negligible abundance of the dark
green species, particularly for NCOR. There appeared to be an abundant presence of corepressor and
SR10171/SR11023-bound heterodimer, suggesting that SR10171 and SR11023 strongly encourage core-
pressor binding.
These findings suggest that distinct coregulator recruitment profiles is a key factor in the mechanism of
antagonism of PPARg. The preferential recruitment of corepressors over coactivators by our compounds
leads to repressive effects on the transcription of PPARg-controlled genes.
DISCUSSION
Understanding the details of PPARg modulation by ligands is critical for obtaining effective insulin sensiti-
zation while limiting the incidence of adverse side effects due to superfluous activation of the receptor. It
has been made evident that antagonists and inverse agonists are the most promising approach asiScience 5, 69–79, July 27, 2018 75
antidiabetic agents for their abilities to normalize insulin sensitivity while minimizing PPARg transactivation
and hence minimizing side effects.
Crystal structures of PPARg LBD to date have demonstrated a conserved backbone fold with little variation
in H12 (Bruning et al., 2007; Hughes et al., 2012). We hypothesize that the lack of a distinct antagonist struc-
ture in PPARg found to date could be due to one or more of the following reasons: (1) crystal artifacts that
stabilize H12 in the agonist conformation are very common in PPARg LBD co-crystal structures, (2) several of
the antagonist-bound PPARg structures have bound coactivator peptides that force H12 in the agonist
conformation, (3) PPARg ligands have been found to bind in more than one conformation in solution
studies but are generally locked in one conformation in crystal structures and this may have precluded
the ability to see the H12 destabilized version of the structure, and (4) there may be multiple and/or
different mechanisms of antagonism in PPARg with only a certain class having been captured in the few
antagonist-bound PPARg structures solved to date.
We have obtained crystal structures of an inverse agonist and an antagonist bound to PPARg LBD, which show
H12 in an alternate orientation similar to antagonist conformations reported in other nuclear receptors. The
attainment of these crystal structures overcomes the hurdles stated previously that have thus far prevented crys-
tal structures being solved with H12 in the antagonist position. The absence of a coactivator peptide as well as
crystallization in a space group novel to PPARg LBD has enabled the resolving of the antagonist H12 conforma-
tion in PPARg. This has important implications in the field of PPARg research, as it provides the first structural
insight into the mechanism of antagonism in PPARg as a result of modulation by non-activating ligands.
The consequences of the antagonist H12 conformation appear to have a direct effect on coregulator recruit-
ment, as exhibited by our native MS data that showed a minimal presence of SR10171/SR11023-bound het-
erodimer complexed with coactivator peptide. The structural mechanism behind this can be hypothesized
by analyzing the crystal structure of the active complex: PPARg LBD bound to rosiglitazone and coactivator
peptide. Previous crystal structures of PPARg LBD bound to coactivator peptide have demonstrated essen-
tial interactions between the peptide and AF2 of PPARg. Residues of H12 are critical for making interactions
with the LXXLLmotif of nuclear receptor coactivators (Nolte et al., 1998). A highly conservedGlu471 of H12 in
nuclear receptors is involved in an extensive hydrogen bond network with residues of the coactivator pep-
tide, as well as participating in a charge clamp alongside Lys301 of H3 to lock the coactivator peptide in
place (Nolte et al., 1998). This highlights the importance of H12 conformation for interacting with the
remainder of the AF2 to stabilize this region, allowing coactivators to bind. The antagonist conformation
of H12 in our crystal structures does not participate in the AF2 surface, excluding the formation of the essen-
tial hydrogen bond network normally contributed by Glu471 of H12 to lock the coactivator peptide in place.
This abrogates coactivator binding in a physiological context, consistent with our native MS data.
In addition to this, our nativeMSdata revealed that corepressor peptides were able to bind to the PPARg/RXRa
heterodimer in the presence of SR10171 or SR11023 and not when rosiglitazone was bound to the heterodimer.
Superimposition of corepressor-bound PPARa LBD with SR10171, SR11023, and rosiglitazone-bound PPARg
crystal structures reveals a clash between the corepressor bound to PPARa and the active conformation of
H12 of rosiglitazone-bound PPARg (Figure S4). The antagonist conformation of H12 in PPARa results in a larger
pocket to accommodate corepressor binding (Xu et al., 2002). This is pertinent to PPARg, which shows analmost
identical antagonist H12 orientation to PPARa when bound to SR10171 or SR11023. This suggests that, in the
PPARg system, SR10171 and SR11023 attract H12 to the antagonist conformation, which opens the core-
pressor-binding cleft to enable SMRT andNCORbinding to the receptor. This is a feasible reason for the abun-
dant corepressorbindingexhibited in thepresenceof SR10171andSR11023shown innativeMS, aswell asnegli-
gible binding of rosiglitazone to corepressor-bound heterodimer through steric clashing between corepressor
and the active conformation of H12. This can be confirmedby obtaining a crystal structure of PPARg bound to a
corepressor, which should be the focus of future structural studies investigating antagonism in PPARg. From the
current data, it appears that themolecularmechanismof antagonismby these compounds is through preferen-
tial recruitment of corepressors over coactivators, thereby lowering activation of PPARg target genes. Attempts
weremade to complement nativeMSusing surfaceplasmon resonancebut itwas shown tobe intractableowing
to the hydrophobicity of the compounds.
The structural mechanism of PPARg antagonism in our crystal structures differs from that of PPARa. What
is most strikingly different between the PPARg and the PPARa antagonist structures is the differing ligand-
binding modes. In the case of PPARa, GW6471 wraps around the buried surface of H3 and extends toward76 iScience 5, 69–79, July 27, 2018
Figure 5. PPARg H12 Shifts to the Antagonist Conformation in a Mechanistically Distinct Manner to Other
Nuclear Receptor LBDs
Protein molecules are shown as green ribbons, with helix 12 highlighted in red. Respective ligands are shown as yellow
sticks.
(A–C) (A) ERa bound to antagonist Raloxifene (PDB: 1ERR), (B) ERb bound to Raloxifene (PDB: 1QKN), and (C) PPARa
bound to antagonist GW6471 show that steric clashing by the ligands pushes H12 into the antagonist conformation.
(D) Our crystal structures of PPARg bound to antagonists show that the ligands pull H12 into the antagonist conformation,
a novel mechanism distinct from other nuclear receptors.the space usually occupied by the active H12 conformation, as well as occupies the space near the b-sheet.
This contrasts with our crystal structures, where SR10171 and SR11023 are positioned entirely within the
b-sheet side of H3, making no contacts with the region of the binding pocket closest to the AF2 surface.
Crystal structures of PPARa, ERa, and ERb bound to antagonists show that H12 shifts to the antagonist
conformation through steric clashing between the ligand and the active H12 conformation, where the
antagonist forces H12 out of the active position (Brzozowski et al., 1997; Shiau et al., 1998; Xu et al.,
2002). The crystal structure of PPARa bound to antagonist GW6471 shows that the ligand protrudes out
of the space between H3 and H11 to sterically clash with H12, forcing it out of the active position and
into a dynamic and destabilized state, to the point where the secondary structure of the helix has been dis-
torted in the crystal structure for this region. In our crystal structures of PPARg, SR10171 and SR11023 do not
occupy the space between H3, H12, and H11 in PPARg to force H12 out of the active conformation but are
instead located between H3 and the b-sheet to ‘‘pull’’ H12 into the antagonist conformation (Figure 5). We
have hypothesized that PPARg antagonism operates via a ‘‘tumble and trap’’ mechanism, where ‘‘tumble’’
refers to the dynamic nature of H12 in solution in the absence of ligand, where upon the addition of
SR10171 or SR11023 H12 is ‘‘trapped’’ in the antagonist conformation mediated by interactions with the
ligands. This is mechanistically distinct from PPARa and highlights the uniqueness of SR10171 and
SR11023 in their ligand-binding modes to exert their non-activating properties. In both cases, the resultingiScience 5, 69–79, July 27, 2018 77
outcome of the ligands despite their mechanisms is that H12 can move away from the AF2 surface, which
opens up the corepressor-binding cleft. This suggests some conservation in the mechanism of antagonism
through the structural consequences of H12 conformation in PPARs, independent of the underlying mech-
anism that results in the allosteric shift in H12.
Our findings reveal what may be only onemechanism of antagonism in PPARg, with other possibilities likely
as well. For example, it has been shown that SR1664 exhibits its mechanism of antagonism by sterically
clashing with Phe282 to destabilize the AF2 region, hindering the coactivator-binding capacity of the re-
ceptor (Marciano et al., 2015a). Both mechanisms result in the disruption of the AF2 surface, which appears
to be a key factor in repressing transcription of target genes in PPARg.
In summary, we present here the first report of an antagonist and inverse agonist conformation of H12 in
PPARg. Our crystal structures show that SR10171 and SR11023 induce an allosteric shift in H12, pulling it
away from the ligand-dependent AF2 coactivator-binding face, which consequently abrogates transcrip-
tionally promoting coactivator recruitment to the LBD. This shift in H12 conformation simultaneously en-
ables corepressor recruitment through exposing the corepressor-binding pocket, to enable recruitment
of transcriptionally suppressing corepressors to give SR10171 and SR11023 their non-activating properties.
The mechanism by which H12 is allosterically shifted in PPARg by the ligands is unique from other nuclear
receptors, as H12 undergoes a tumble and trap motion, unseen in other nuclear receptors. This represents
an exciting development toward understanding the mechanism of antagonism and inverse agonism in
PPARg, as well as aiding in further drug design to treat type 2 diabetes.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Transparent Methods and four figures and can be found with this article
online at https://doi.org/10.1016/j.isci.2018.06.012.
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